Clindamycin

DRUG INFORMATION

  ADULT
    - The recommended dosage of XACIATO is one applicatorful (5 g of vaginal gel
      containing 100 mg of clindamycin) administered once intravaginally as a single
      dose at any time of the day [see Clinical Studies ( 14 )] .
      Source: US FDA label for clindamycin (XACIATO), section 'dosage and
      administration', retrieved 2026-08-29
    - Administer one applicatorful (5 g of gel containing 100 mg of clindamycin) once
      intravaginally as a single dose at any time of the day.
      Source: US FDA label for clindamycin (XACIATO), section 'dosage and
      administration', retrieved 2026-08-29
    - The recommended dosage of XACIATO is one applicatorful (5 g of vaginal gel
      containing 100 mg of clindamycin) administered once intravaginally as a single
      dose at any time of the day [see Clinical Studies ( 14 )] . Place the used tube
      with any remaining gel and used applicator in the container box and deposit in a
      trash container after use [see Instructions for Use ] . XACIATO is not for
      ophthalmic, dermal, or oral use.
      Source: US FDA label for clindamycin (XACIATO), section 'dosage and
      administration', retrieved 2026-08-29

  CHILD
    - The safety and effectiveness of XACIATO have been established in females aged 12
      years and older for the treatment of bacterial vaginosis. Use of XACIATO for this
      indication is supported by the extrapolation of clinical trial data from adequate
      and well controlled clinical studies in adult women. The safety and effectiveness
      of XACIATO have not been established in pediatric patients younger than 12 years
      of age for the treatment of bacterial vaginosis.
      Source: US FDA label for clindamycin (XACIATO), section 'pediatric use', retrieved
      2026-08-29

  RENAL IMPAIRMENT
    - No kidney-impairment dose in this label. Not a statement that none is needed.
      Source: Read and found silent: the US FDA label for clindamycin (XACIATO),
      retrieved 2026-08-29

  HEPATIC IMPAIRMENT
    - No liver-impairment dose in this label. Not a statement that none is needed.
      Source: Read and found silent: the US FDA label for clindamycin (XACIATO),
      retrieved 2026-08-29

  PREGNANCY
    - Risk Summary Other clindamycin vaginal products have been used to treat pregnant
      women during the second and third trimester.
      Source: US FDA label for clindamycin (XACIATO), section 'pregnancy', retrieved
      2026-08-29
    - XACIATO has not been studied in pregnant women.
      Source: US FDA label for clindamycin (XACIATO), section 'pregnancy', retrieved
      2026-08-29
    - However, based on the low systemic absorption of XACIATO following the
      intravaginal route of administration in nonpregnant women, maternal use is not
      likely to result in significant fetal exposure to the drug [see Clinical
      Pharmacology ( 12.3 )] .
      Source: US FDA label for clindamycin (XACIATO), section 'pregnancy', retrieved
      2026-08-29

  BREASTFEEDING
    - Vaginal administration of XACIATO to pregnant/lactating female rats during a pre-
      and post-natal development (gestation day 6 through gestation day 21) study at 2
      mg clindamycin phosphate/day had no adverse effects on dams or their offspring.
      Source: US FDA label for clindamycin (XACIATO), section 'use in specific
      populations', retrieved 2026-08-29
    - The developmental and health benefits of breastfeeding should be considered along
      with the mother's clinical need for clindamycin and any potential adverse effects
      on the breastfed child from clindamycin or from the underlying maternal condition.
      Source: US FDA label for clindamycin (XACIATO), section 'use in specific
      populations', retrieved 2026-08-29